Integra (IART) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2025, Integra LifeSciences (IART) reported revenue of $434.93 million, down 1.7% over the same period last year. EPS came in at $0.83, compared to $0.97 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $434.35 million, representing a surprise of +0.13%. The company delivered an EPS surprise of +4.73%, with the consensus EPS estimate being $0.79.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Organic Revenue Growth: -2.5% versus the three-analyst average estimate of -3.5%.
• Revenue- Codman Specialty Surgical- Total: $323.31 million versus $306.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.8% change.
• Revenue- Tissue Technologies- Private Label: $31.64 million compared to the $24.41 million average estimate based on two analysts. The reported number represents a change of +19.6% year over year.
• Revenue- Tissue Technologies- Wound Reconstruction and Care: $79.98 million versus the two-analyst average estimate of $99.43 million. The reported number represents a year-over-year change of -21.2%.
• Revenue- Tissue Technologies- Total: $111.62 million versus the two-analyst average estimate of $123.85 million. The reported number represents a year-over-year change of -12.8%.

View all Key Company Metrics for Integra here>>>

Shares of Integra have returned +6.5% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research